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 Purpose: To evaluate short-acting bronchodilator effects in chronic ob-
structive pulmonary disease (COPD) by using hyperpolarized 
helium 3 ( 3 He) magnetic resonance (MR) imaging, spirometry, 
and plethysmography.
 Materials and 
Methods: 
Fourteen ex-smokers with COPD provided written informed con-
sent to a local ethics board–approved and Health Insurance and 
Portability Accountability Act–compliant protocol and underwent 
hyperpolarized  3 He and hydrogen 1 MR imaging, spirometry, and 
plethysmography before and a mean of 25 minutes  6 2 (standard 
deviation) after administration of 400  m g salbutamol. Distribution 
of  3 He gas was evaluated by using semiautomated segmentation of 
 3 He voxel intensities, where cluster 1 represented regions of signal 
void or ventilation defect volume (VDV), and clusters 2–5 (C2–C5) 
represented gradations of signal intensity from hypointensity (C2) 
to hyperintensity (C5).  3 He ventilation defect percentage (VDP) 
was calculated as VDV normalized to the thoracic cavity volume. 
Comparisons of pre- and post-salbutamol means were performed 
by using a two-way mixed-design repeated measures analysis of 
variance, and comparisons of the magnitude of the treatment effect 
between pulmonary function and  3 He MR imaging measurements 
were performed by using effect size (ES) calculations. The relation-
ships between pulmonary function and  3 He MR imaging fi ndings 
were determined by using Spearman correlation coeffi cients.
 Results: After salbutamol administration, there were signifi cant changes 
in forced expiratory volume in 1 second (FEV 1 ) ( P = .001), 
total lung capacity ( P = .04), and functional residual capacity 
( P = .03), as well as VDP ( P  , .0001) and  3 He gas distribution 
(C2,  P = .01; C3,  P = .03; C4,  P  , .0001; and C5,  P = .02). Treat-
ment ES was greater for  3 He VDP than for FEV 1 (0.50 vs 0.22). 
There was a signifi cant correlation between baseline VDP and 
post-salbutamol FEV 1 change ( r =  2 0.77,  P = .001). Although fi ve 
patients were classifi ed as bronchodilator responders and nine 
patients were classifi ed as bronchodilator nonresponders accord-
ing to American Thoracic Society and European Respiratory So-
ciety criteria, there was no signifi cant difference in the magnitude 
of the  3 He MR imaging changes after salbutamol administration 
between responder groups.
 Conclusion:  3 He MR imaging depicted signifi cant improvements in the dis-
tribution of  3 He gas after bronchodilator therapy in ex-smokers 
with COPD with and those without clinically important changes 
in FEV 1 .
 q RSNA, 2011
Supplemental material :  http://radiology.rsna.org/lookup/suppl
/doi:10.1148/radiol.11110403/-/DC1 
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MR imaging would provide the neces-
sary and suffi cient spatial and tempo-
ral sensitivity, as well as precision, 
to depict any potential regional func-
tional lung changes after bronchodi-
lator therapy. Therefore, our aim was 
to evaluate short-acting bronchodilator 
effects in COPD by using hyperpolar-
ized  3 He MR imaging, spirometry, and 
plethysmography. 
 Materials and Methods 
 Patients 
 All patients provided written informed 
consent to the study protocol, which was 
approved by the local research ethics 
board and Health Canada, and the study 
was compliant with the Personal In-
formation Protection and Electronic 
Documents Act of Canada and the 
Health Insurance Portability and Ac-
countability Act of the United States. 
The use of an on-site  3 He gas polarizer 
(HeliSpin; GE Healthcare, Durham, NC) 
as well as the limitation of standard 
measures of expiratory airfl ow for eval-
uating the regional nature of bronchodi-
lator response, is motivating the evalu-
ation of new methods ( 10,11 ), including 
those based on noninvasive imaging 
( 12–15 ). For example, computed tomog-
raphy (CT) has been used to evaluate 
changes in airway morphology after ad-
ministration of salbutamol ( 12,13 ) and 
tiotropium ( 14,15 ) and showed greater 
post-bronchodilator response in patients 
with COPD with mainly airway disease 
compared with those with mainly em-
physema ( 16 ). Additionally, a recent sin-
gle photon emission computed tomog-
raphy/CT and multiple breath nitrogen 
washout study ( 17 ) reported no signifi -
cant change in ventilation heterogeneity 
after tiotropium administration. 
 Pulmonary magnetic resonance (MR) 
imaging with hyperpolarized helium 3 
( 3 He) has emerged as a functional im-
aging method that provides high-spatial-
resolution and high-temporal-resolution 
( 18–23 ) images of the lung. Regional ven-
tilation abnormalities are clearly visual-
ized as areas of decreased  3 He signal in 
the lung that can be scored or quanti-
fi ed with the metric ventilation defect 
percentage (VDP) ( 19 ) or percentage 
ventilated volume ( 24 ).  3 He MR imag-
ing ventilation abnormalities have previ-
ously been evaluated in COPD ( 25–30 ) 
with measurements that are sensitive to 
the pathologic changes that accompany 
COPD ( 24 ), have high same-day and 
short-term reproducibility ( 20,21 ), and 
reveal signifi cant longitudinal changes 
over 2 years before changes in FEV 1 
are observed ( 18 ). Because of previous 
reproducibility ( 20,21 ) and longitudinal 
( 18 ) fi ndings, we hypoth esized that  3 He 
 Chronic obstructive pulmonary dis-ease (COPD) is characterized by progressive expiratory fl ow limita-
tion that develops because of the com-
bined effects of large and small airway 
dysfunction and increased lung compli-
ance related to the permanent destruc-
tive changes of emphysema ( 1 ). Gas trap-
ping and dynamic lung hyperinfl ation 
are major consequences of decreased 
expiratory airfl ow and often lead to many 
of the disabling symptoms associated 
with COPD, such as dyspnea and lim-
itation of exercise capacity ( 2,3 ). After 
smoking cessation, bronchodilators are 
the fi rst-line therapy in the symptomatic 
management of COPD ( 3 ), and assess-
ment of acute response to bronchodila-
tors is often based on spirometric mea-
surements of forced expiratory volume 
in 1 second (FEV 1 ). Although spirometric 
measurements provide the most com-
mon primary end point for clinical trials 
evaluating therapeutic response, rela-
tively poor correlations have been re-
ported between FEV 1 and other clinical 
measurements of COPD ( 4–6 ). In other 
words, symptomatic relief after bron-
chodilator use often occurs with only 
modest improvements in FEV 1 ( 7–9 ), 
underscoring the apparent discordance 
between spirometric measurements and 
COPD symptoms, quality of life, and 
functional measurements. 
 The discordance between spiromet-
ric measurements and COPD symptoms, 
 Implication for Patient Care 
 Our results indicate that signifi - n
cant gas distribution improve-
ments occur even in patients with 
COPD with minimal forced expi-
ratory volume in 1 second or 
forced vital capacity response to 
salbutamol; these fi ndings are 
relevant to our understanding of 
the regional and functional 
effects of bronchodilators. 
 Advances in Knowledge 
 Helium 3 (  n 3 He) MR imaging mea-
surements of gas distribution 
showed signifi cant improvements 
( P  , .0001) after salbutamol 
administration in ex-smokers 
with chronic obstructive pulmo-
nary disease (COPD), providing 
evidence of the regional and 
physiologic effects of therapy. 
 Signifi cant improvements (  n P  , 
.0001) in  3 He gas distribution 
after bronchodilator administra-
tion were detected by using 
hyperpolarized  3 He MR imaging in 
COPD, regardless of spirometry-
based bronchodilator response 
classifi cation. 
 Published online before print 
 10.1148/radiol.11110403  Content code:  
Radiology 2011; 261:283–292
 Abbreviations: 
 ATS = American Thoracic Society 
 COPD = chronic obstructive pulmonary disease 
 D LCO = diffusing capacity of lung for carbon monoxide 
 ES = effect size 
 FEV 1 = forced expiratory volume in 1 second 
 FRC = functional residual capacity 
 FVC = forced vital capacity 
 GOLD = Global Initiative for Chronic Obstructive Lung 
Disease 
 Sa O 2 = arterial oxygen saturation 
 SDD = smallest detectable difference 
 TLC = total lung capacity 
 VDP = ventilation defect percentage 
 VDV = ventilation defect volume 
 Author contributions: 
 Guarantors of integrity of entire study, R.E., D.G.M., G.P.; 
study concepts/study design or data acquisition or data 
analysis/interpretation, all authors; manuscript drafting 
or manuscript revision for important intellectual content, 
all authors; manuscript fi nal version approval, all authors; 
literature research, M.K., M.H., G.P.; clinical studies, M .K., 
L.M., R.E., D.G.M., G.P.; statistical analysis, M.K., L.M., G.P.; 
and manuscript editing, all authors 
 Potential confl icts of interest are listed at the end 
of this article. 
Radiology: Volume 261: Number 1—October 2011 n radiology.rsna.org 285
 THORACIC IMAGING: Quantifying Bronchodilator Effects in COPD with  3 He MR Imaging Kirby et al
MR image segmentation ( 33–35 ), to clas-
sify the  3 He MR imaging voxel intensity 
values into clusters ranging from 1 to 5, 
representing gradations of signal inten-
sity from no signal (cluster 1) and hy-
pointense signal (cluster 2) to hyperin-
tense signal (cluster 5) and generating 
a  3 He voxel cluster map ( Fig 1b ). To ob-
tain the external contour of the thoracic 
cavity to differentiate ventilation defects 
(cluster 1) from the edge of the lung,  1 H 
MR images were segmented by using a 
seeded region-growing algorithm ( 36 ) 
and were registered to the  3 He MR ven-
tilation images as previously described 
( 37 ). VDP was generated by using VDV, 
or cluster 1, normalized to the thoracic 
cavity volume as previously described 
( 19 ). For the remaining ventilation clus-
ters, the segmented  1 H thoracic cavity 
volume was used to generate a cluster 
percentage representing a normalized 
 3 He cluster volume for the lung. All 
measurements were performed by the 
same observer (M.K., with 3 years of 
experience performing manual  3 He MR 
image segmentation and 1 year of ex-
perience developing and performing 
semiautomated  3 He MR image segmen-
tation), who was blinded to patient and 
time point, with time point random-
ized to reduce any potential measure-
ment bias. Reproducibility of the semi-
automated method was determined 
on the basis of the pre-salbutamol intrao-
bserver variability of fi ve repeated mea-
surements for fi ve patients with COPD. 
The smallest detectable difference (SDD), 
or the minimum change in  3 He measure-
ments that could be measured confi -
dently in individual patients—not due 
to observer measurement variability, for 
fi ve of the patients with COPD was 2% 
for VDP and 0.4%, 1%, 0.6%, and 0.3% 
for clusters 2–5, respectively. 
 Statistical Analysis 
 Multivariate analysis of variance and 
repeated-measures analysis of variance 
were performed for comparison of pre- 
and post-salbutamol pulmonary function 
and lung volume measurements by using 
software (SPSS, version 16.0; SPSS, 
Chicago, Ill). A two-way mixed-design 
analysis of variance was used (with SPSS) 
to determine the interactions between 
pulmonary function technologist during 
all inspiration breath-hold acquisitions. 
Because of this extensive coaching, no 
correction for differences in inspiration 
levels between breath-hold acquisitions 
for individual patients was required. 
Pulse oximetry was used to measure 
arterial oxygen saturation (Sa O 2 ) for all 
patients during imaging sessions; an 
adverse event was considered to have oc-
curred when Sa O 2 decreased below 88% 
at any time during the imaging session. 
Study withdrawal was required when 
Sa O 2 decreased to 80% for 10 seconds 
or longer. 
 Conventional hydrogen 1 ( 1 H) MR 
imaging was performed before hyper-
polarized  3 He MR imaging, with patients 
imaged during a 1.0-L breath-hold of 
 4 He/nitrogen 2 (N 2 ) by using a whole-
body radiofrequency coil and a  1 H fast 
spoiled gradient-recalled echo sequence 
(total data acquisition time, 16 sec-
onds; repetition time msec/echo time 
msec, 4.7/1.2; fl ip angle, 30°; fi eld of 
view, 40  3 40 cm; matrix, 256  3 128; 
14 sections; 15-mm section thickness; 
no gap), as previously described ( 21 ). 
 Prior to  3 He MR imaging, a polarizer 
system (HeliSpin; GE Healthcare) was 
used to polarize  3 He gas to 30%–40%, 
and doses of 5 mL per kilogram of body 
weight, diluted with ultra–high purity 
medical-grade nitrogen (Spectra Gases, 
Alpha, NJ), were administered in 1.0-L 
Tedlar bags. As previously described 
( 21 ), hyperpolarized  3 He coronal static 
ventilation images were acquired dur-
ing a breath-hold of a 1.0-L  3 He/N 2 mix-
ture (total data acquisition time, 14  sec-
onds; 4.3/1.4; fl ip angle, 7°; bandwidth, 
31 .25 kHz; fi eld of view, 40  3 40 cm; 
matrix, 128  3 128; 14 sections; 15-mm 
section thickness; no gap). 
 Image Analysis 
 Semiautomated segmentation of  3 He 
pulmonary ventilation MR images was 
performed by using custom software that 
had been generated by using MATLAB 
R2007b (Mathworks, Natick, Mass), as 
previously described ( 31 ). Briefl y, and 
as shown in the schematic in  Figure 1 , 
 3 He MR images were evaluated by using 
k-means cluster analysis ( 32 ), similar 
to previously described methods for  3 He 
was provided to Robarts Research In-
stitute through an agreement with GE 
Healthcare for which we pay $100 000 
Canadian annually.  
 Fourteen patients with a clinical di-
agnosis of COPD who were ex-smokers 
with a smoking history of at least 10 
pack-years and who had Global Initiative 
for Chronic Obstructive Lung Disease 
(GOLD) stage II–IV disease were en-
rolled. Patients were required to refrain 
from using both short-acting and long-
acting bronchodilators on the morning 
of the study. Prebronchodilator MR im-
aging was performed immediately after 
pulmonary function testing; postbron-
chodilator MR imaging and pulmonary 
function testing were performed a mean 
of 25 minutes  6 2 (standard deviation) 
after administration of 400  m g salbuta-
mol sulfate USP (Apo-Salvent CFC Free 
Inhalation Aerosol; Apotex, Toronto, 
Ontario, Canada), which was inhaled by 
using a spacer device. 
 Pulmonary Function Testing 
 Spirometry was performed using an 
EasyOne spirometer (ndd Medizintechnik, 
Zurich, Switzerland) according to the 
American Thoracic Society (ATS) guide-
lines. Static lung volumes and diffus-
ing capacity of lung for carbon mon-
oxide (D LCO ) were measured by using 
body plethysmography (MedGraphics, 
St Paul, Minn). 
 Image Acquisition 
 MR imaging was performed with a whole-
body 3.0-T MR imaging system (Excite 
12.0; GE Healthcare, Milwaukee, Wis) 
with broadband imaging capability as 
previously described ( 21 ), and  3 He MR 
imaging was enabled by using a single-
channel rigid elliptical transmit-receive 
chest coil (RAPID Biomedical, Wuerz-
burg, Germany). It is important to note 
that we endeavored to minimize the 
potential for differences in the levels 
of inspiration between the breath-hold 
acquisitions for each patient by  (a) con-
ducting training and practice sessions 
for all patients before MR imaging re-
lated to the inspiration breath-hold ma-
neuver from functional residual capacity 
(FRC) and  (b) continuous coaching and 
monitoring at the MR imaging table by a 
286 radiology.rsna.org n Radiology: Volume 261: Number 1—October 2011
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 Pulmonary Function Measurements 
 Table 2 shows mean pulmonary function 
and  3 He MR imaging measurements 
for all patients, and Table E1 (online), 
provides a per-patient list of all mea-
surements. Statistically signifi cant post-
salbutamol changes were observed 
for FEV 1 ( P = .001, ES = 0.22), TLC 
( P = .04, ES =  2 0.34), and FRC ( P = .03, 
ES =  2 0.10). 
 Imaging Measurements 
 Figure 2 shows two central coronal  3 He 
MR imaging sections, on which the tra-
chea and two main bronchi are clearly 
visible and  3 He ventilation is displayed in 
red, registered to the gray-scale  1 H MR 
images of the thorax for each of the fi ve 
representative patients (two patients with 
GOLD stage II disease, two patients with 
GOLD stage III disease, and one patient 
with GOLD stage IV disease) before and 
after salbutamol administration. To en-
sure that the increased distribution of 
 3 He gas after salbutamol administra-
tion was not due to differences in the 
volume of polarized gas administered at 
each time point, we calculated the total 
pixel intensity for each lung image, in-
cluding the trachea and major airways, 
from the image pixel intensity frequency 
histograms, as well as the total moles of 
polarized gas delivered for each patient 
time point (data not shown). These es-
timations showed that the amount of 
polarized gas administered and inhaled 
was not signifi cantly different between 
time points ( P = .87). The signal-to-noise 
ratio for each pre- and post-salbutamol 
image pair was also not signifi cantly 
different ( P = .12). To minimize the 
potential of introducing intensity varia-
tions because of  B 1 fi eld inhomogeneity, 
patients were located in the same po-
sition within the coil between imaging 
time points. 
 Table 2 shows mean normalized 
pre- and post-salbutamol  3 He measure-
ments, and Table E2 (online) shows 
the mean pre- and post-salbutamol  3 He 
volume and signal intensity measure-
ments. There was a signifi cant decrease 
in VDP after salbutamol administration 
( P  , .0001, ES =  2 0.50), and there was 
no relationship between post-salbuta-
mol changes in VDP and image section 
the method of Eliasziw et al ( 39 ), as 
shown in Equation (2): 
  
Dt intraSDD 2SEMz  , (2) 
 where  z  a  is 1.96, corresponding to a 
signifi cance level of  a = .05, and SEM intra 
is the standard error of measurement 
due to intraobserver variability and is 
calculated as shown in Equation (3): 
   V 2intra ˆSEM e  , (3) 
 where  V 2ˆ e  is the intraobserver repeated-
measures variance. Linear regression 
( r 2 values) and Spearman correlation 
coeffi cients ( r values) were calculated 
to determine the relationships between 
pulmonary function and  3 He MR imag-
ing measurements by using software 
(Prism, version 4.0; GraphPad Software, 
San Diego, Calif). In all statistical analy-
ses, results were considered signifi cant 
when the probability of making a type I 
error was less than 5% ( P  , .05). 
 Results 
 Patient Demographics 
 Patient demographic characteristics are 
provided in  Table 1 for 14 ex-smokers 
with COPD (fi ve with GOLD stage II 
disease, eight with GOLD stage III dis-
ease, and one with GOLD stage IV 
disease). 
patients and treatment, imaging section 
and treatment, and bronchodilator re-
sponse group and treatment for all  3 He 
MR imaging measurements. Effect size 
(ES) calculations allowed the magnitude 
of an effect to be compared between 
disparate types of measurements ( 38 ). 
Therefore, for comparison of the mag-
nitude of the treatment effect between 
pulmonary function and imaging mea-
surements, treatment ES was calculated 
as the ratio of the mean difference be-
tween pre- and post-salbutamol mea-
surements and the pooled standard devi-
ation for all patients, calculated by using 
Hedges  g as shown in Equation (1): 
 
 
   
 
post pre
2 2
post post pre pre
post pre
( 1)SD ( 1)SD
2
x x
g
n n
n n  
,  (1)
 
 where  prex  and  postx  are the mean pre- 
and post-salbutamol measurement for 
all patients, SD pre and SD post are the 
standard deviations of the pre- and post-
salbutamol measurements for all pa-
tients, and  n pre and  n post are the numbers 
of patients evaluated before and after 
salbutamol administration. The SDD, 
defi ned as the smallest difference that 
can be measured with prospectively 
determined confi dence that is not due 
to measurement error (variability), was 
calculated for fi ve repeated pre-salbutamol 
 3 He VDP measurements according to 
 Figure 1 
  
 Figure 1:  A, Coronal  3 He MR image and,  B,  3 He cluster map generated with semiautomated cluster analy-
sis and segmentation for all sections.  3 He ventilation defect volume ( VDV ) = cluster 1, while VDP = cluster 1 
normalized to thoracic cavity volume. 
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ES =  2 0.66), and cluster 5 ( P = .02, ES = 
 2 0.33). On the basis of pre-salbutamol 
intraobserver variance, the SDD, or the 
minimum change in  3 He measurements 
that could be measured confi dently in 
individual patients that was not due 
to observer measurement variability, 
for fi ve of the patients with COPD (one 
with stage II disease and four with stage 
III disease) was 2% for VDP and 0.4%, 
1%, 0.6%, and 0.3% for clusters 2–5, 
respectively. 
 As shown in  Figure 3 , there were 
signifi cant and moderate Spearman cor-
relations between baseline  3 He VDP and 
post-salbutamol changes in FEV 1 ( r = 
 2 0.77,  P = .001) and between baseline 
FEV 1 as a percentage predicted value 
and post-salbutamol changes in FEV 1 ( r = 
0.56,  P = .04). There was also a sig-
nifi cant correlation between the changes 
measured in  3 He cluster 2 and changes 
in FEV 1 ( r =  2 0.62,  P = .02) and FVC 
( r =  2 0.59,  P = .03). 
 Bronchodilator Responders and 
Nonresponders 
 Published ATS and European Respira-
tory Society guidelines ( 40 ) defi ne a sig-
nifi cant bronchodilator response as an 
increase in post-salbutamol FEV 1 and/or 
FVC greater than 200 mL and 12%. 
Accordingly, fi ve patients were classifi ed 
as bronchodilator responders and nine 
patients were classifi ed as bronchodilator 
nonresponders. As shown in  Table 3 and 
Table E1 (online), mean reductions in 
VDP and cluster 2 and corresponding 
increases in clusters 3–5 were demon-
strated for both responders and nonre-
sponders. As shown in  Figure 4 , VDP 
was signifi cantly lower for responders 
than for nonresponders at baseline and 
after bronchodilator administration ( P = 
.03). As depicted by the parallel slopes for 
pre- and post-salbutamol measurements 
shown in  Figure 4 , there was no sig-
nifi cant difference between responders 
and nonresponders for post-salbutamol 
change at  3 He MR imaging (VDP, clus-
ters 2–5,  P  . .05). It is important 
to point out that there was a single 
nonresponding patient who showed a 
240-mL and 12% improvement in FEV 1 
(just missing the  . 12% change in 
FEV 1 requirement for bronchodilator 
was a signifi cant decrease in  3 He clus-
ter 2 ( P = .01, ES =  2 0.50) and signifi -
cant increases in  3 He cluster 3 ( P = .03, 
ES =  2 0.20), cluster 4 ( P  , .0001, 
(as a region of interest) ( P = .30), in-
dicating no bias for any measurable 
changes with respect to image section. 
After salbutamol administration, there 
 Table 1 
 Demographic Data in 14 Patients 
Parameter Datum
Age (y) 70  6 6 (61–77)
 Men 70  6 6 (61–77)
 Women 71  6 6 (64–77)
No. of men 8
Body mass index (kg/m 2 ) 24.9  6 3.8 (17.6–31.4)
FEV 1 (L) 1.23  6 0.50 (0.63–2.18)
FEV 1 * 45  6 12 (28–61)
FVC (L) 2.98  6 0.83 (1.52–4.44)
FVC * 83  6 12 (65–107)
FEV 1 /FVC 41  6 10 (22–60)
TLC (L) 7.12  6 1.27 (4.82–8.96)
TLC * 122  6 20 (101–175)
Inspiratory capacity (L) 2.21  6 0.54 (1.39–3.09)
Inspiratory capacity * 83  6 16 (58–108)
FRC (L) 4.89  6 1.22 (3.14–7.27)
FRC * 155  6 42 (110–243)
Reserve volume (L) 3.83  6 0.94 (2.63–5.25)
Reserve volume * 170  6 53 (104–285)
D LCO * 43  6 19 (20–89)
Note.—Unless otherwise specified, data are means  6 standard deviations, with ranges in parentheses. FVC = forced vital 
capacity, TLC = total lung capacity.
* Data are percentage predicted values.
 Table 2 
 Pre- and Post-Salbutamol Measurements in 14 Patients 
Parameter Pre-Salbutamol Post-Salbutamol  P Value * ES
Pulmonary function measurement (L)
 FEV 1 1.23  6 0.50 1.35  6 0.57) .001 0.22
 FVC 2.98  6 0.83 3.06  6 0.85) .46 0.10
 TLC 7.05  6 1.22 6.62  6 1.26 † .04  2 0.35
 Inspiratory capacity 2.15  6 0.58 2.02  6 0.66 † .39  2 0.21
 FRC 4.89  6 1.22 4.61  6 1.22 † .03  2 0.23
 Reserve volume 3.79  6 0.91 3.59  6 0.85 † .23  2 0.23
Hyperpolarized  3 He MR imaging 
  measurement (%)
 VDP 28  6 7 24  6 9  , .0001  2 0.50
 Cluster 2 15  6 2 14  6 2 .01  2 0.50
 Cluster 3 31  6 5 32  6 5 .03 0.20
 Cluster 4 19  6 4 22  6 5  , .0001 0.66
 Cluster 5 8  6 3 9  6 3 .02 0.33
Note.—Unless otherwise specifi ed, data are means  6 standard deviations. 
* Calculated with repeated-measures analysis of variance for the pulmonary function measurements and two-way mixed-design 
repeated-measures analysis of variance for the MR imaging measurements.
 † Available for 13 patients.
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measurements of gas distribution and 
their effect sizes,  (b) a signifi cant rela-
tionship between  3 He VDP and changes 
in FEV 1 after salbutamol administration, 
and  (c) changes at  3 He MR imaging after 
bronchodilator administration that were 
not signifi cantly different for responder 
and nonresponder subgroups. 
 Discussion 
 In this pilot functional MR imaging 
eval uation of bronchodilator effects in 
COPD, we made a number of observa-
tions and report the following:  (a) signifi -
cant postbronchodilator improvements 
in both spirometric and  3 He MR imaging 
response), and when this patient 
was recategorized as a responder, the 
reported results remained the same. 
It is also worth noting that there were 
no signifi cant differences between re-
sponders and nonresponders in terms 
of baseline FEV 1 ( P = .44) or D LCO 
( P  . .99). 
 Figure 2 
  
 Figure 2: Pre- and post-salbutamol  3 He MR images (in red) registered to two center coronal thoracic  1 H MR images (in gray 
scale) for fi ve representative patients with COPD. The patients in  S1 and  S2 had GOLD stage II disease, the patients in  S3 
and  S4 had GOLD stage III disease, and the patient in  S5 had GOLD stage IV disease. The change in  3 He gas distribution after 
salbutamol is readily apparent in the right and left apical regions in  S1 and  S5 and in the right mid-apical region in  S3, whereas 
there is little change visible in  S2 and  S4 for the two sections shown. 
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 First, and as might be expected 
from previous work that demonstrated 
modest improvements in lung function 
in patients with COPD after broncho-
dilator therapy ( 7,10,11,41–43 ), we ob-
served statistically signifi cant changes in 
mean FEV 1 , FRC, and TLC. At the same 
time, signifi cant decreases in  3 He MR 
 Figure 3 
  
 Figure 3: Graphs show correlation between  (a) baseline  (BL) FEV 
1
 as percentage predicted value ( %pred  ) 
and post-salbutamol change in FEV 
1
 (in liters) and  (b) baseline VDP and post-salbutamol change in FEV 
1
 .  (a) 
Baseline FEV 
1
 is signifi cantly correlated with  D FEV 
1
 ( r = 0.60,  r  2 = 0.36,  P = .02,  y = 0.006 ·  2 0.13) and 
 (b) baseline VDP is signifi cantly correlated with  D FEV 
1
 ( r =  2 0.68,  r  2 = 0.46,  P = .008,  y =  2 0.01 · +0.42). 
Dotted lines = 95% confi dence intervals. 
 Table 3 
 Per-Patient Changes in Spirometric and  3 He MR imaging Measurements after Salbutamol Administration 
Patient Group and No.
Spirometry  3 He MR Imaging
 D FEV 
1
 *  D FVC *  D VDP (%)  D Cluster 2 (%)  D Cluster 3 (%)  D Cluster 4 (%)  D Cluster 5 (%)
All Patients 0.12/10 0.07/2  2 4  2 1 1 3 1
Responders
 Patient 1 0.14/11 0.46/14 2  2 1  2 1 0 0
 Patient 3 0.18/16 0.42/13 2  2 1 0 0  2 2
 Patient 5 0.32/15 0.36/10  2 14  2 2 2 9 5
 Patient 7 0.18/25 0.24/16 0 1 1 0  2 1
 Patient 10 0.27/22 0.49/21  2 11  2 4 4 6 4
 All 0.22/11 0.36/14  2 4  2 1 1 3 1
Nonresponders
 Patient 2 0.02/2  2 0.01/0 0 0 1 0  2 1
 Patient 4 0.04/6  2 0.25/ 2 11 2  2 1 0  2 1  2 1
 Patient 6 0.00/0  2 0.32/ 2 12 3  2 1  2 2 0  2 1
 Patient 8  2 0.06/ 2 7  2 0.07/ 2 3  2 6  2 3 3 5 1
 Patient 9 0.24/12 0.35/9  2 2 0  2 2 2 2
 Patient 11 0.08/9 0.11/3  2 8 0  2 5 9 4
 Patient 12 0.06/8  2 0.08/ 2 4  2 20  2 2 10 10 2
 Patient 13 0.13/9 0.07/2  2 3  2 1  2 1 2 3
 Patient 14 0.07/4  2 0.76/ 2 17  2 6 1 7 0  2 2
 All 0.06/5  2 0.11/ 2 3  2 5  2 1 1 3 1
Note.—Signifi cant bronchodilator response was defi ned as an increase in FEV 1 and/or FVC greater than 200 mL and 12% from pre-salbutamol values according to ATS/ European Respiratory Society 
guidelines ( 40 ).
* Data are liters/percentage change from baseline absolute value in liters.
 Figure 4 
  
 Figure 4: Graph shows mean changes in  3 He VDP 
for bronchodilator responders (black line) and nonre-
sponders (gray line). Values are means calculated 
for all patient imaging sections, and error bars = 
95% confi dence intervals. 
of gas distribution improvements. This 
fi nding is in agreement with those of a 
recent CT study ( 15 ) that demonstrated 
regionally dispersed airway wall struc-
tural alterations after bronchodilator 
administration. Moreover, when ES was 
imaging VDP and cluster 2 and signifi -
cant improvements in  3 He MR imaging 
clusters 3–5 were measured, suggesting 
regional gas distribution improvements 
throughout the lung. Additionally, the 
 3 He gas distribution changes occurred in 
different sections for each patient, with 
no detected bias for specifi c regions 
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clear for all imaging studies that stan-
dardization is required for reproducible 
and comparable breath-hold volumes, 
and this is critically important for acute 
and chronic therapy repeated studies. 
We also acknowledge that although  3 He 
MR imaging ventilation defect measure-
ments have been previously reported to 
have high same-day reproducibility ( 20 ) 
in the majority of patients included in 
this study, the prospective inclusion of a 
control group would have strengthened 
the conclusion that the post-salbutamol 
changes observed here were directly at-
tributable to bronchodilator treatment. 
Another important consideration is the 
limited access to  3 He MR imaging and 
the high cost of  3 He gas that has thus far 
restricted translation of this functional 
imaging method to specialized MR phys-
ics centers. It is important to note the 
development of hyperpolarized xenon 
129 MR imaging, a less expensive and 
more readily available approach, and a 
promising alternative against which these 
reported fi ndings can be directly tested. 
 In conclusion, our results suggest 
that noninvasive pulmonary functional 
 3 He MR imaging provides a way to mea-
sure acute treatment effects by quan-
tifying  3 He gas distribution before and 
after therapy for COPD. 
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